Jump Financial LLC Purchases 139,624 Shares of uniQure (NASDAQ:QURE)

Jump Financial LLC grew its holdings in uniQure (NASDAQ:QURE - Free Report) by 193.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 211,776 shares of the biotechnology company's stock after acquiring an additional 139,624 shares during the period. Jump Financial LLC owned about 0.43% of uniQure worth $3,740,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Twin Tree Management LP purchased a new stake in shares of uniQure in the fourth quarter worth about $77,000. FNY Investment Advisers LLC purchased a new stake in shares of uniQure in the fourth quarter worth about $88,000. ADAR1 Capital Management LLC purchased a new stake in shares of uniQure in the fourth quarter worth about $177,000. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 969 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after acquiring an additional 1,503 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Trading Up 1.5 %

Shares of NASDAQ:QURE traded up $0.22 on Wednesday, hitting $14.61. 651,512 shares of the company's stock were exchanged, compared to its average volume of 1,361,419. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The stock has a market capitalization of $790.06 million, a price-to-earnings ratio of -2.95 and a beta of 0.42. The business's 50 day simple moving average is $11.91 and its two-hundred day simple moving average is $11.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on QURE shares. Royal Bank of Canada reissued an "outperform" rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. Chardan Capital started coverage on uniQure in a research note on Tuesday, April 1st. They set a "buy" rating and a $38.00 price objective on the stock. StockNews.com raised uniQure to a "sell" rating in a research note on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of uniQure in a research note on Monday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.80.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares of the company's stock, valued at $2,240,441.70. The trade was a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.